DLBCL: Major New Treatment Breakthroughs
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.
MDedge News
source https://www.medscape.com/viewarticle/992149?src=rss
MDedge News
source https://www.medscape.com/viewarticle/992149?src=rss
Comments
Post a Comment